EDIT insider transaction filings
Editas Medicine, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-09. Screen EDIT transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 7 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings by 3 insiders — 11,892 shares, $33,999 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: sale of 5,124 shares @ $3.04 ($15,563) by O'Neill Gilmore Neil, filed 2026-09-04.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| O'Neill Gilmore Neil — CEO, Director | 1 | — | 1 leg · 5,124 sh · $15,563 | — |
| Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | 2 | — | 2 legs · 5,637 sh · $15,311 | — |
| Parison Amy — SVP, Chief Financial Officer | 2 | — | 2 legs · 1,131 sh · $3,125 | — |
| Ellinor Patrick Thomas II — Director | 1 | — | — | 1 |
| Ory Daniel Scott — EVP, Chief Medical Officer | 1 | — | — | 1 |
Recent Form 4 filings — Editas Medicine, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Ory Daniel Scott — EVP, Chief Medical Officer | Grant/award (A): 950,000 (derivative) @ $0 | EDGAR |
| 2026-09-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 709 @ $3.04 | EDGAR |
| 2026-09-04 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 5,124 @ $3.04 | EDGAR |
| 2026-09-04 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 453 @ $3.04 | EDGAR |
| 2026-08-07 | 4 | Ellinor Patrick Thomas II — Director | Grant/award (A): 103,400 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 678 @ $2.58 | EDGAR |
| 2026-07-29 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 4,928 @ $2.67 | EDGAR |
| 2026-06-22 | 4 | Connaughton Bernadette — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Scadden David — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Levy Elliott M. — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Hopfield Jessica — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Hirsch Andrew — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 464 @ $2.70 | EDGAR |
| 2026-06-05 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 15,380 @ $2.70 | EDGAR |
| 2026-06-05 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 731 @ $2.70 | EDGAR |
| 2026-03-16 | 4 | O'Neill Gilmore Neil — CEO, Director | Grant/award (A): 1,015,200 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Parison Amy — SVP, Chief Financial Officer | Grant/award (A): 292,856 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Grant/award (A): 292,856 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 5,394 @ $2.02 | EDGAR |
| 2026-03-04 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 474 @ $2.02 | EDGAR |
| 2026-03-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 749 @ $2.02 | EDGAR |
| 2025-12-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 713 @ $2.15 | EDGAR |
| 2025-12-04 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 5,603 @ $2.15 | EDGAR |
| 2025-12-04 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 461 @ $2.15 | EDGAR |
| 2025-09-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 710 @ $2.60 | EDGAR |
| 2025-09-04 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 458 @ $2.60 | EDGAR |
| 2025-09-04 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 5,592 @ $2.60 | EDGAR |
| 2025-08-08 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 679 @ $2.58 | EDGAR |
| 2025-08-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 5,121 @ $2.49 | EDGAR |
| 2025-06-10 | 4 | Scadden David — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Levy Elliott M. — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Connaughton Bernadette — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Hopfield Jessica — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Hirsch Andrew — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 446 @ $1.72 | EDGAR |
| 2025-06-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 726 @ $1.72 | EDGAR |
| 2025-06-04 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 15,192 @ $1.72 | EDGAR |
| 2025-04-08 | 4 | Parison Amy — SVP, Chief Financial Officer | Grant/award (A): 34,672 (derivative) @ $0 | EDGAR |
| 2025-03-27 | 4 | Lucera Erick — EVP, CHIEF FINANCIAL OFFICER | Grant/award (A): 275,100 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-03-27 | 4 | O'Neill Gilmore Neil — CEO, Director | Grant/award (A): 828,000 (derivative) @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-03-27 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Grant/award (A): 275,100 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Lucera Erick — EVP, CHIEF FINANCIAL OFFICER | Sale (S): 4,109 @ $1.71 | EDGAR |
| 2025-03-05 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 16,632 @ $1.71 | EDGAR |
| 2025-03-05 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 2,891 @ $1.71 | EDGAR |
| 2024-12-05 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 1,618 @ $2.08 | EDGAR |
| 2024-12-05 | 4 | Mei Baisong — EVP, CHIEF MEDICAL OFFICER | Sale (S): 541 @ $2.08 | EDGAR |
| 2024-09-06 | 4 | Mei Baisong — EVP, CHIEF MEDICAL OFFICER | Sale (S): 518 @ $3.42 | EDGAR |
| 2024-09-06 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 1,555 @ $3.42 | EDGAR |
| 2024-07-26 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 11,886 @ $5.42 | EDGAR |
| 2024-07-22 | 4 | Mei Baisong — EVP, CHIEF MEDICAL OFFICER | Sale (S): 6,619 @ $5.21 | EDGAR |
Recent 8-K events — Editas Medicine, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-26 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-07 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EDIT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →